Table of Content

1 Key Insights

2 Executive Summary of Progressive Supranuclear Palsy

3 SWOT Analysis for Progressive Supranuclear Palsy

4 Progressive Supranuclear Palsy (PSP) Market Overview at a Glance
4.1 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2017
4.2 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2030

5 Disease Background and Overview
5.1 Introduction
5.2 Signs and symptoms
5.3 Phenotypes of Progressive Supranuclear Palsy
5.4 History
5.5 Associated risk factors
5.6 Genetics
5.7 Pathophysiology
5.8 PSP associated abnormalities
5.9 Clinical Presentation and Assessment
5.1 Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria
5.11 PET Imaging as a Biomarker in Tauopathies

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Patient Population of Progressive Supranuclear Palsy [PSP]

7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)
7.1 The United States
7.1.1 Assumptions and Rationale
7.1.2 Total Prevalent Patient Population of PSP in the United States
7.1.3 Phenotype associated with PSP in the United States
7.1.4 Gender specific Prevalence of PSP in the United States
7.1.5 Comorbidities associated with PSP in the United States
7.2 EU5 Countries
7.2.1 Assumptions and Rationale
7.2.2 Germany
7.2.2.1 Total Prevalent Patient Population of PSP in Germany
7.2.2.2 Phenotype associated with PSP in Germany
7.2.2.3 Gender specific Prevalence of PSP in Germany
7.2.2.4 Comorbidities associated with PSP in Germany
7.2.3 France
7.2.3.1 Total Prevalent Patient Population of PSP in France
7.2.3.2 Phenotype associated with PSP in France
7.2.3.3 Gender specific Prevalence of PSP in France
7.2.3.4 Comorbidities associated with PSP in France
7.2.4 Italy
7.2.4.1 Total Prevalent Patient Population of PSP in Italy
7.2.4.2 Phenotype associated with PSP in Italy
7.2.4.3 Gender specific Prevalence of PSP in Italy
7.2.4.4 Comorbidities associated with PSP in Italy
7.2.5 Spain
7.2.5.1 Total Prevalent Patient Population of PSP in Spain
7.2.5.2 Phenotype associated with PSP in Spain
7.2.5.3 Gender specific Prevalence of PSP in Spain
7.2.5.4 Comorbidities associated with PSP in Spain
7.2.6 The United Kingdom
7.2.6.1 Total Prevalent Patient Population of PSP in the United Kingdom
7.2.6.2 Phenotype associated with PSP in the United Kingdom
7.2.6.3 Gender specific Prevalence of PSP in the United Kingdom
7.2.6.4 Comorbidities associated with PSP in the United Kingdom
7.3 Japan
7.3.1 Assumptions and Rationale
7.3.2 Total Prevalent Patient Population of PSP in Japan
7.3.3 Phenotype associated with PSP in Japan
7.3.4 Gender specific Prevalence of PSP in Japan
7.3.5 Comorbidities associated with PSP in Japan

8 Treatment
8.1 Current symptomatic treatment

9 Unmet Needs

10 Emerging drugs
10.1 AZP2006: Alzprotect
10.1.1 Product Description
10.1.2 Other Development Activities
10.1.3 Clinical Development
10.1.3.1 Clinical Trials Information
10.1.4 Safety and efficacy
10.2 UCB0107: UCB Biopharma
10.2.1 Product Description
10.2.2 Product Development Activity
10.2.3 Clinical Development
10.2.3.1 Clinical Trials Information
10.2.4 Safety and efficacy
10.3 RT001: Retrotope
10.3.1 Product Description
10.3.2 Other Development Activities
10.3.3 Safety and efficacy

11 Other promising candidates
11.1 NBMI: EmeraMed
11.1.1 Product Description
11.1.2 Clinical Development
11.2 Antisense oligonucleotide: Novartis
11.2.1 Product Description
11.2.2 Clinical Development
11.2.2.1 Clinical trials information

12 No development reported
12.1 ASN 120290: Asceneuron
12.1.1 Product Description
12.1.2 Other Development Activities
12.1.3 Clinical Development
12.1.4 Safety and efficacy

13 Discontinued therapies
13.1 ABBV-8E12: AbbVie
13.1.1 Product Description
13.2 Gosuranemab: Biogen
13.2.1 Product Description

14 Progressive Supranuclear Palsy (PSP): Seven Major Market Analysis
14.1 Key Findings
14.2 Total Market Size of PSP in 7MM
14.3 Market Outlook: 7MM

15 United States
15.1 Total Market size of PSP
15.2 PSP Market Size by Therapies

16 EU5 Countries
16.1 Germany
16.1.1 Total Market size of PSP
16.1.2 PSP Market Size by Therapies
16.2 France
16.2.1 Total Market size of PSP
16.2.2 PSP Market Size by Therapies
16.3 Italy
16.3.1 Total Market size of PSP
16.3.2 PSP Market Size by Therapies
16.4 Spain
16.4.1 Total Market size of PSP
16.4.2 PSP Market Size by Therapies
16.5 United Kingdom
16.5.1 Total Market size of PSP
16.5.2 PSP Market Size by Therapies

17 Japan
17.1 Total Market size of PSP
17.2 PSP Market Size by Therapies

18 Market Drivers

19 Market Barriers

20 Appendix
20.1 Bibliography
20.2 Report Methodology

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight



List of Figures


Figure 1: SWOT Analysis
Figure 2: Tau isoforms and conformations
Figure 3: Tau hyperphosphorylation and aggregation
Figure 4: Total Prevalent Patient Population of PSP in 7MM (2017–2030)
Figure 5: Prevalence of PSP in the United States (2017–2030)
Figure 6: Phenotype associated with PSP in the United States (2017–2030)
Figure 7: Gender-specific Prevalence of PSP in the United States (2017–2030)
Figure 8: Comorbidities associated with PSP in the United States (2017–2030)
Figure 9: Prevalence of PSP in Germany (2017–2030)
Figure 10: Phenotype associated with PSP in Germany (2017–2030)
Figure 11: Gender-specific Prevalence of PSP in Germany (2017–2030)
Figure 12: Comorbidities associated with PSP in Germany (2017–2030)
Figure 13: Prevalence of PSP in France (2017–2030)
Figure 14: Phenotype associated with PSP in France (2017–2030)
Figure 15: Gender-specific Prevalence of PSP in France (2017–2030)
Figure 16: Comorbidities associated with PSP in France (2017–2030)
Figure 17: Prevalence of PSP in Italy (2017–2030)
Figure 18: Phenotype associated with PSP in Italy (2017–2030)
Figure 19: Gender-specific Prevalence of PSP in Italy (2017–2030)
Figure 20: Comorbidities associated with PSP in Italy (2017–2030)
Figure 21: Prevalence of PSP in Spain (2017–2030)
Figure 22: Phenotype associated with PSP in Spain (2017–2030)
Figure 23: Gender-specific Prevalence of PSP in Spain (2017–2030)
Figure 24: Comorbidities associated with PSP in Spain (2017–2030)
Figure 25: Prevalence of PSP in the United Kingdom (2017–2030)
Figure 26: Phenotype associated with PSP in the United Kingdom (2017–2030)
Figure 27: Gender-specific Prevalence of PSP in the United Kingdom (2017–2030)
Figure 28: Comorbidities associated with PSP in the United Kingdom (2017–2030)
Figure 29: Prevalence of PSP in Japan (2017–2030)
Figure 30: Phenotype associated with PSP in Japan (2017–2030)
Figure 31: Gender-specific Prevalence of PSP in Japan (2017–2030)
Figure 32: Comorbidities associated with PSP in Japan (2017–2030)
Figure 33: Potential therapeutic targets for progressive supranuclear palsy
Figure 34: Potential therapeutic targets for progressive supranuclear palsy
Figure 35: Unmet Needs of PSP
Figure 36: Seven Major Market Size of PSP in USD Million (2017–2030)
Figure 37: Market Size of PSP in the United States, USD Millions (2017–2030)
Figure 38: The US market size of PSP by therapies in USD Million (2017–2030)
Figure 39: Market Size of PSP in Germany, USD Millions (2017–2030)
Figure 40: Germany market size of PSP by therapies in USD Million (2017–2030)
Figure 41: Market Size of PSP in France, USD Millions (2017–2030)
Figure 42: France market size of PSP by therapies in USD Million (2017–2030)
Figure 43: Market Size of PSP in Italy, USD Millions (2017–2030)
Figure 44: Italy market size of PSP by therapies in USD Million (2017–2030)
Figure 45: Market Size of PSP in Spain, USD Millions (2017–2030)
Figure 46: Spain market size of PSP by therapies in USD Million (2017–2030)
Figure 47: Market Size of PSP in the UK, USD Millions (2017–2030)
Figure 48: The UK market size of PSP by therapies in USD Million (2017–2030)
Figure 49: Market Size of PSP in Japan, USD Millions (2017–2030)
Figure 50: Japan market size of PSP by therapies in USD Million (2017–2030)
Figure 51: Market Drivers
Figure 52: Market Barriers


List of Tables


Table 1: Summary of Progressive Supranuclear Palsy (PSP) Market, Epidemiology, and Key Events (2017–2030)
Table 2: Core clinical features
Table 3: Supportive Features
Table 4: Diagnostic criteria for PSP
Table 5: Total Prevalent Patient Population of PSP in 7MM (2017–2030)
Table 6: Total Prevalent Population of PSP in the United States (2017–2030)
Table 7: Phenotype associated with PSP in the United States (2017–2030)
Table 8: Gender-specific Prevalence of PSP in the United States (2017–2030)
Table 9: Comorbidities associated with PSP in the United States (2017–2030)
Table 10: Total Prevalent Population of PSP in Germany (2017–2030)
Table 11: Phenotype associated with PSP in Germany (2017–2030)
Table 12: Gender-specific Prevalence of PSP in Germany (2017–2030)
Table 13: Comorbidities associated with PSP in Germany (2017–2030)
Table 14: Total Prevalent Population of PSP in France (2017–2030)
Table 15: Phenotype associated with PSP in France (2017–2030)
Table 16: Gender-specific Prevalence of PSP in France (2017–2030)
Table 17: Comorbidities associated with PSP in France (2017–2030)
Table 18: Total Prevalent Population of PSP in Italy (2017–2030)
Table 19: Phenotype associated with PSP in Italy (2017–2030)
Table 20: Gender-specific Prevalence of PSP in Italy (2017–2030)
Table 21: Comorbidities associated with PSP in Italy (2017–2030)
Table 22: Total Prevalent Population of PSP in Spain (2017–2030)
Table 23: Phenotype associated with PSP in Spain (2017–2030)
Table 24: Gender-specific Prevalence of PSP in Spain (2017–2030)
Table 25: Comorbidities associated with PSP in Spain (2017–2030)
Table 26: Total Prevalent Population of PSP in the United Kingdom (2017–2030)
Table 27: Phenotype associated with PSP in the United Kingdom (2017–2030)
Table 28: Gender-specific Prevalence of PSP in the United Kingdom (2017–2030)
Table 29: Comorbidities associated with PSP in the United Kingdom (2017–2030)
Table 30: Total Prevalent Population of PSP in Japan (2017–2030)
Table 31: Phenotype associated with PSP in Japan (2017–2030)
Table 32: Gender-specific Prevalence of PSP in Japan (2017–2030)
Table 33: Comorbidities associated with PSP in Japan (2017–2030)
Table 34: AZP2006, Clinical Trial Description, 2020
Table 35: UCB0107, Clinical Trial Description, 2020
Table 33: Antisense oligonucleotide, Clinical Trial Description, 2020
Table 36: Seven Major Market Size of PSP in USD Million (2017–2030)
Table 37: The US Market size of PSP in USD Million (2017–2030)
Table 38: The US market size of PSP by Therapies in USD Million (2017–2030)
Table 39: Germany Market size of PSP in USD Million (2017–2030)
Table 40: Germany market size of PSP by Therapies in USD Million (2017–2030)
Table 41: France Market size of PSP in USD Million (2017–2030)
Table 42: France market size of PSP by Therapies in USD Million (2017–2030)
Table 43: Italy Market size of PSP in USD Million (2017–2030)
Table 44: Italy market size of PSP by Therapies in USD Million (2017–2030)
Table 45: Spain Market size of PSP in USD Million (2017–2030)
Table 46: Spain market size of PSP by Therapies in USD Million (2017–2030)
Table 47: The UK Market size of PSP in USD Million (2017–2030)
Table 48: The UK market size of PSP by Therapies in USD Million (2017–2030)
Table 49: Japan Market size of PSP in USD Million (2017–2030)
Table 50: Japan market size of PSP by Therapies in USD Million (2017–2030)